CER Daily Newsfeed

ISPOR 2025 Daily Round-Ups: Day 1

(5/14, Joanne Walker, Katie McCool, Laura Dormer, The Evidence Base) reports “...Jon Campbell (National Pharmaceutical Council) discussed method sharing, emphasizing that HTA relies not only on rigorous science but also on contextual judgment and transparency. He highlighted HEMA’s work to define best practices in HTA methodology and urged stakeholders to recognize how values and funding sources shape assessments. He concluded that HTA methods should be seen as tools not rules and must be applied with nuance.” Full

Exclusive: Datavant to Acquire Real-World Data Specialist Aetion, Doubling Life Sciences Team

(5/15, Andrew Dunn, Endpoints News) reports “The health tech company Datavant is acquiring Aetion, a rival in the real-world data space, Endpoints News exclusively reports. Datavant on Thursday plans to announce the deal, which will double the size of its life sciences team to roughly 400 employees.” Subscription Required

Most Favored Nation Policy 'Lazy, Misguided,' But US Price Reforms Politically 'Inevitable'

(5/15, Cathy Kelly, Pink Sheet) reports “...[University of Washington professor Sean Sullivan] said the policy is lazy because ‘importing prices from other countries that have been determined through value assessments done by those countries’ careful evaluations of drugs, applying social constructs … should not ‘replace the hard work we should do as a country [on] those same value assessments.’ And it is ‘misguided because the view that other countries will raise their prices if we lower ours is naive and it shows a real lack of understanding of how other countries do [health technology assessments] and make decisions,’ Sullivan added.” Subscription Required

RFK Jr. Open To Working With Sanders On 'Most Favored Nation' Bill

(5/14, Maaisha Osman, Inside Health Policy) reports “...Sanders' plan to introduce a new bill on MFN policy comes after President Donald Trump signed an executive order Monday (May 12) that gives drug makers 30 days to voluntarily bring U.S. prices down to those of other developed countries or face formal regulatory action by the administration requiring them to do so...Kennedy responded that he supports the concept and is willing to work with Sanders on the upcoming legislation.” Subscription Required

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

(5/15, Francesca Bruce, Pink Sheet) reports “...BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.” Subscription Required